Silvia Baroncelli

List of Publications by Year
in descending order

37 papers	823 citations	758635 12 h-index	500791 28 g-index
38 all docs	38 docs citations	38 times ranked	955 citing authors

#	Article	IF	Citations
1	Long-Term Subjective and Objective Assessment of Smell and Taste in COVID-19. Cells, 2022, 11, 788.	1.8	10
2	Seroprevalence of Brucella Infection in a Cohort of HIV-Positive Malawian Pregnant Women Living in Urban Areas. Vector-Borne and Zoonotic Diseases, 2022, , .	0.6	1
3	Immunoglobulin G passive transfer from mothers to infants: total IgG, IgG subclasses and specific antipneumococcal IgG in 6-week Malawian infants exposed or unexposed to HIV. BMC Infectious Diseases, 2022, 22, 342.	1.3	3
4	Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers. Npj Vaccines, 2022, 7, 44.	2.9	2
5	Dried blood spots for the quantitative evaluation of IgG isotypes and correlation with serum samples in HIV-exposed uninfected (HEU) infants. Journal of Immunological Methods, 2021, 493, 113019.	0.6	4
6	HIV-exposed infants with EBV infection have a reduced persistence of the immune response to the HBV vaccine. AIDS Research and Therapy, 2021, 18, 48.	0.7	3
7	Dynamics of immunoglobulin G subclasses during the first two years of life in Malawian infants born to HIV-positive mothers. BMC Pediatrics, 2020, 20, 181.	0.7	6
8	Markers of microbial translocation during pregnancy: differences among HIV+ women of African and European provenance. Journal of Infection in Developing Countries, 2020, 14, 184-190.	0.5	0
9	IgG abnormalities in HIV-positive Malawian women initiating antiretroviral therapy during pregnancy persist after 24 months of treatment. International Journal of Infectious Diseases, 2019, 88, 1-7.	1.5	4
10	Immune Activation and Microbial Translocation Markers in HIV-Exposed Uninfected Malawian Infants in the First Year of Life. Journal of Tropical Pediatrics, 2019, 65, 617-625.	0.7	6
11	Soluble <scp>CD</scp>14 levels in plasma and breastmilk of Malawian <scp>HIV</scp>+ women: Lack of association with morbidity and mortality in their exposed infants. American Journal of Reproductive Immunology, 2018, 79, e12812.	1.2	4
12	Deficit of IgG2 in HIV-positive pregnant women is responsible of inadequate IgG2 levels in their HIV-uninfected children in Malawi. Medical Microbiology and Immunology, 2018, 207, 175-182.	2.6	3
13	HIVâ€1 DNA dynamics and variations in HIVâ€1 DNA protease and reverse transcriptase sequences in multidrugâ€resistant patients during successful raltegravirâ€based therapy. Journal of Medical Virology, 2016, 88, 2115-2124.	2.5	7
14	Antibodies against pneumococcal capsular polysaccharide in Malawian HIV-positive mothers and their HIV-exposed uninfected children. Infectious Diseases, 2016, 48, 317-321.	1.4	6
15	Rate and Determinants of Residual Viremia in Multidrug-Experienced Patients Successfully Treated with Raltegravir-Based Regimens. AIDS Research and Human Retroviruses, 2015, 31, 71-77.	0.5	9
16	Anti-Streptococcus pneumoniae and rotavirus IgG levels in HIV-positive women do not correlate with maternal status and infant morbidity and mortality. Journal of Medical Microbiology, 2015, 64, 795-797.	0.7	2
17	HIV-1 coreceptor switch during 2Âyears of structured treatment interruptions. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 1565-1570.	1.3	4
18	Interindividual and Intra-Individual Variabilities of Darunavir and Ritonavir Plasma Trough Concentrations in Multidrug Experienced HIV Patients Receiving Salvage Regimens. Therapeutic Drug Monitoring, 2013, 35, 785-790.	1.0	3

#	Article	IF	Citations
19	Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors. International Journal of STD and AIDS, 2012, 23, 459-463.	0.5	10
20	Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy. Journal of Antimicrobial Chemotherapy, 2012, 67, 1479-1485.	1.3	10
21	Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines. Retrovirology, 2012, 9, 69.	0.9	21
22	Hematological effects of zidovudine prophylaxis in newborn infants with and without prenatal exposure to zidovudine. Journal of Medical Virology, 2011, 83, 551-556.	2.5	13
23	Common occurrence of anaemia at the end of pregnancy following exposure to zidovudine-free regimens. Journal of Infection, 2011, 63, 144-150.	1.7	3
24	Antiretroviral Treatment in Pregnancy: A Six-Year Perspective on Recent Trends in Prescription Patterns, Viral Load Suppression, and Pregnancy Outcomes. AIDS Patient Care and STDs, 2009, 23, 513-520.	1.1	39
25	Development and use of SIV-based Integrase defective lentiviral vector for immunization. Vaccine, 2009, 27, 4622-4629.	1.7	41
26	Response to Segat et al. â€˜Are DEFB1 gene polymorphisms associated with HIV-1 infection and virus replication?â€™. Aids, 2009, 23, 649-650.	1.0	0
27	Viral outcome of simianâ€“human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys. Archives of Virology, 2008, 153, 463-472.	0.9	18
28	Macaca mulatta,fascicularisandnemestrinain AIDS vaccine development. Expert Review of Vaccines, 2008, 7, 1419-1434.	2.0	45
29	Single-nucleotide polymorphisms in human Î²-defensin-1 gene in Mozambican HIV-1-infected women and correlation with virologic parameters. Aids, 2008, 22, 1515-1517.	1.0	33
30	Characterization ofÎ±-Defensins Plasma Levels inMacaca Fascicularisand Correlations with Virological Parameters during SHIV89.6Pcy11Experimental Infection. AIDS Research and Human Retroviruses, 2007, 23, 287-296.	0.5	6
31	T cell receptor excision circles (TRECs) analysis during acute intrarectal infection of cynomolgus monkeys with pathogenic chimeric simian human immunodeficiency virus. Virus Research, 2007, 126, 86-95.	1.1	3
32	Successful Immunization with a Single Injection of Non-integrating Lentiviral Vector. Molecular Therapy, 2007, 15, 1716-1723.	3.7	79
33	Identification of a cytotoxic T-lymphocyte (CTL) epitope recognized by Gag-specific CTLs in cynomolgus monkeys infected with simian/human immunodeficiency virus. Journal of General Virology, 2006, 87, 3385-3392.	1.3	11
34	Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge. Journal of General Virology, 2004, 85, 1191-1201.	1.3	63
35	Circular viral DNA detection and junction sequence analysis from PBMC of SHIV-infected cynomolgus monkeys with undetectable virus plasma RNA. Virology, 2004, 324, 531-539.	1.1	12
36	SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. Journal of Medical Primatology, 2003, 29, 193-208.	0.3	51

#	Article	IF	Citations
37	Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nature Medicine, 1999, 5, 643-650.	15.2	288